New Partnership Accelerates Push for Oral Metabolic Breakthroughs

Deep Apple Therapeutics and Novo Nordisk team on a non incretin oral target, stirring new momentum in metabolic research

18 Nov 2025

Deep Apple Therapeutics and Novo Nordisk have formed a research partnership to develop an oral therapy for metabolic disease based on a non-incretin G-protein-coupled receptor target, widening efforts beyond today’s dominant injectable drugs. The project remains at an early discovery stage but reflects rising interest in pill-based treatments that could reach larger patient groups.

The agreement comes amid strong global demand for advanced weight-management medicines. Each new clinical result in the field has increased pressure for therapies that are easier to administer and simpler to distribute. By pursuing a mechanism outside the incretin class that underpins many current products, the two companies aim to open a new therapeutic category. Analysts warn that significant scientific hurdles remain but note that broader mechanisms may reduce strain on existing supply chains.

Deep Apple will lead early research, using its discovery platform to identify potential compounds. Once a lead candidate is selected, Novo Nordisk plans to oversee clinical development and regulatory testing. The arrangement could reach a value of up to $812mn, underscoring the competition to secure next-generation metabolic therapies. A senior Novo executive said the programme formed part of efforts to build a more versatile portfolio for patients seeking long-term treatment options.

Industry specialists view the collaboration as another indication of a rapidly shifting market. Companies active in obesity care are increasingly relying on partnerships to keep pace with scientific advances, and many expect a gradual move toward oral drugs to influence how treatment is delivered. The outlook remains uncertain, but interest from investors and clinicians continues to grow.

Researchers caution that designing a safe and effective oral therapy for complex metabolic disorders is technically demanding and requires extensive safety data. Even so, experts argue that the complementary capabilities of the two organisations provide a strong starting point. Further alliances are expected as the sector expands and research ambitions rise.